Core Viewpoint - Athira Pharma is advancing its clinical development of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS), with a focus on demonstrating safety and efficacy in upcoming trials [2][3][5]. Clinical Development & Pipeline Programs - ATH-1105 is a next-generation small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is involved in neuroprotection and anti-inflammatory pathways [4][5]. - The Phase 1 clinical trial of ATH-1105 was completed in November 2024, involving 80 healthy volunteers, and showed a favorable safety profile [8]. - Full results from the Phase 1 trial are expected to be shared in the second half of 2025, with plans to begin dosing ALS patients by late 2025 [3][8]. Financial Results - As of March 31, 2025, the company reported cash, cash equivalents, and investments totaling $36.7 million, down from $51.3 million at the end of 2024 [12]. - Research and Development (R&D) expenses for the quarter were $4.3 million, significantly lower than $21.2 million for the same period in 2024, primarily due to reduced costs associated with the fosgonimeton program [12]. - The net loss for the quarter was $9.1 million, or $0.23 per share, compared to a net loss of $26.3 million, or $0.69 per share, for the same quarter in 2024 [12][19]. Upcoming Presentation - Athira will present Phase 1 and nonclinical efficacy data for ATH-1105 at the 4th Annual ALS Drug Development Summit from May 12-14, 2025, in Boston, Massachusetts [6][7].